Vitamin D metabolite and calcium phosphorus metabolism in in patients with primary hyperparathyroidism on the background of bolus therapy with colecalciferol

BACKGROUND: Vitamin D (25-hydroxyvitamin D [25(ОН)D]) deficiency (<20 ng/mL) and insufficiency (20–29 ng/mL) are common in primary hyperparathyroidism (PHPT), but data regarding the vitamin D metabolism in this population is limited.

AIM: The aim of this study is to estimate the vitamin D metabolites and their relationship with the main parameters of phosphorus-calcium metabolism in patients with PHPT at baseline and on the background of a single dose of cholecalciferol 150,000 IU.

MATERIALS AND METHODS: A single-center interventional, dynamic, prospective, comparative study has been carried out. The study included 54 participants, divided into two groups: the 1st group included 27 patients with confirmed PHPT, the 2nd control group (n = 27), matched on gender (p = 0.062). The study included 4 visits; the baseline laboratory examination and a bolus dose of cholecalciferol were performed at the visit 1, the subsequent visits included a dynamic laboratory examination.

RESULTS: Vitamin D deficiency (<20 ng/ml) was detected in 69% of patients with PHPT. In the PHPT group (before cholecalciferol therapy), there was a direct association of 1.25(OH)₂ D₃ with albumin-corrected and ionized calcium, as well as between the 25(OH)D₃ /24.25(OH)₂ D₃ ratio with PTH and magnesium. After taking of cholecalciferol, the levels of 1.25(OH)₂ D₃ and 25(OH)D₃ /24.25(OH)₂ D₃ were significantly increased, and the levels of 25(OH)D₃ /1.25(OH)₂ D₃ were significantly declined at all visits among patients with PHPT. The common 25(OH)D level was comparable to the control group, however the levels of 1,25(OH)₂ D₃ in patients with PHPT were 55% higher at baseline, and after taking of cholecalciferol 150,000 IU. They remained increased by 3–7 days by an additional 23–36%, significantly higher than those in the control group: 44%, 74% and 65%, at visits 2, 3 and 4, respectively (p<0.05). The taking of 150,000 IU cholecalciferol in the PHPT group did not lead to a significant increase in hypercalcemia and hypercalciuria, which indicates the safety of this dose in patients with mild hypercalcemia (albumin corrected calcium <3 mmol/l). None of the study participants experienced any side effects.

CONCLUSION: The completely comprehensive assessment of vitamin D metabolites was carried out for the first time in patients with PHPT before and after using a bolus dose of cholecalciferol. The results confirmed the differences of vitamin D metabolism in chronic excessive secretion of PTH compared to control group, which is new data in the pathogenesis of the disease, and can be used to develop optimal regimens for cholecalciferol taking in this population.

1. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest. 2006;29(6):511-515. doi:10.1007/BF03344140.

2. Silverberg SJ, Walker MD, Bilezikian JP. Asymptomatic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):14-21. doi:10.1016/j.jocd.2012.11.005

3. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63(5):506-513. doi:10.1111/j.1365-2265.2005.02371.x

4. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3561-3569. doi:10.1210/jc.2014-1413

5. Pigarova E.A., Petrushkina A.A. Non-classical effects of vitamin D. Osteoporosis and Bone Diseases. 2017;20(3):90-101. (In Russ.). doi:10.14341/osteo2017390-101

6. Jassil NK, Sharma A, Bikle D, Wang X. Vitamin d binding protein and 25-hydroxyvitamin D levels: emerging clinical applications. Endocr Pract. 2017;23(5):605-613. doi:10.4158/EP161604.RA

7. Clements MR, Davies M, Hayes ME, et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf). 1992;37(1):17-27. doi:10.1111/j.1365-2265.1992.tb02278.x.

8. Tuckey RC, Cheng CYS, Slominski AT. The serum vitamin D metabolome: What we know and what is still to discover. J Steroid Biochem Mol Biol. 2019;186:4-21. doi:10.1016/j.jsbmb.2018.09.003

9. Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017;55(1):3-5. doi:10.1007/s12020-016-1169-1

10. Rao DS, Agarwal G, Talpos GB, et al. Role of vitamin D and calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res. 2002;17 Suppl 2:N75-N80.

11. Pigarova E.A., Rozhinskaya L.Y., Belaya J.E., et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60-84. (In Russ.). doi:10.14341/probl201662460-84

12. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2011 Dec;96(12):3908]. J Clin Endocrinol Metab. 2011;96(7):1911-1930. doi:10.1210/jc.2011-0385

13. Dirks NF, Martens F, Vanderschueren D, et al. Determination of human reference values for serum total 1,25-dihydroxyvitamin D using an extensively validated 2D ID-UPLC-MS/MS method. J Steroid Biochem Mol Biol. 2016;164:127-133. doi:10.1016/j.jsbmb.2015.12.003

14. Tang JCY, Nicholls H, Piec I, et al. Reference intervals for serum 24,25-dihydroxyvitamin D and the ratio with 25-hydroxyvitamin D established using a newly developed LC-MS/MS method. J Nutr Biochem. 2017;46:21-29. doi:10.1016/j.jnutbio.2017.04.005

15. Walker MD, Cong E, Lee JA, et al. Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation. J Clin Endocrinol Metab. 2015;100(9):3443-3451. doi:10.1210/jc.2015-2022

16. Wang X, Shapses SA, Al-Hraishawi H. Free and bioavailable 25-hydroxyvitamin D levels in patients with primary hyperparathyroidism. Endocr Pract. 2017;23(1):66-71. doi:10.4158/EP161434.OR

17. Mokrysheva N.G., Mirnaya S.S., Dedov I.I. et al. Primary hyperparathyroidism in Russia according to the register. Problems of Endocrinology. 2019;65(5):300-310. (in Russ). doi:10.14341/probl10126.

18. Mokrysheva N.G., Eremkina A.K., Mirnaya S.S. et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problems of Endocrinology. 2021;67(4):94-124. (In Russ.). doi:10.14341/probl12801

19. Petrushkina A.A., Pigarova E.A., Rozhinskaya L.Y. The prevalence of vitamin D deficiency in Russian Federation. Osteoporosis and Bone Diseases. 2018;21(3):15-20. (In Russ.). doi:10.14341/osteo10038

20. Fraser DR, Kodicek E. Regulation of 25-hydroxycholecalciferol-1-hydroxylase activity in kidney by parathyroid hormone. Nat New Biol. 1973;241(110):163-166. doi:10.1038/newbio241163a0

21. Wang X, Sheng Z, Meng L, et al. 25-hydroxyvitamin D and vitamin D binding protein levels in patients with primary hyperparathyroidism before and after parathyroidectomy. Front Endocrinol (Lausanne). 2019;10:171. doi:10.3389/fendo.2019.00171

22. Bikle DD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Front Endocrinol (Lausanne). 2019;10:317. doi:10.3389/fendo.2019.00317

23. Kabadi UM. Low 25-hydroxyvitamin D in primary hyperparathyroidism: enhanced conversion into 1,25-hydroxyvitamin D may not be "true" deficiency. JBMR Plus. 2020;4(11):e10415. doi:10.1002/jbm4.10415

24. Meng L, Su C, Shapses SA, Wang X. Total and free vitamin D metabolites in patients with primary hyperparathyroidism [published online ahead of print, 2021 Jul 19]. J Endocrinol Invest. 2021;10.1007/s40618-021-01633-1. doi:10.1007/s40618-021-01633-1

25. Tsuprykov O, Chen X, Hocher CF, et al. Why should we measure free 25(OH) vitamin D?. J Steroid Biochem Mol Biol. 2018;180:87-104. doi:10.1016/j.jsbmb.2017.11.014

26. Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res. 2014;55(1):13-31. doi:10.1194/jlr.R031534

27. Veldurthy V, Wei R, Campbell M, et al. 25-hydroxyvitamin D3 24-hydroxylase: a key regulator of 1,25(OH)2D3 catabolism and calcium homeostasis. Vitam Horm 2016;100:137-50. doi:10.1016/bs.vh.2015.10.005

28. Dai Q, Zhu X, Manson JE, et al. Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial. Am J Clin Nutr. 2018;108(6):1249-1258. doi:10.1093/ajcn/nqy274.

29. Lensmeyer G, Poquette M, Wiebe D, Binkley N. The C-3 epimer of 25-hydroxyvitamin D(3) is present in adult serum. J Clin Endocrinol Metab. 2012;97(1):163-168. doi:10.1210/jc.2011-0584

30. Singh RJ, Taylor RL, Reddy GS, Grebe SK. C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrinol Metab. 2006 Aug;91(8):3055-61. doi:10.1210/jc.2006-0710

31. Brown AJ, Ritter C, Slatopolsky E, et al. 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. J Cell Biochem. 1999 Apr 1;73(1):106-13.

32. Sakurai R, Shin E, Fonseca S, et al. 1alpha,25(OH)2D3 and its 3-epimer promote rat lung alveolar epithelial-mesenchymal interactions and inhibit lipofibroblast apoptosis. Am J Physiol Lung Cell Mol Physiol. 2009;297(3):L496-L505. doi:10.1152/ajplung.90539.2008

33. Bikle D, Bouillon R, Thadhani R, Schoenmakers I. Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status?. J Steroid Biochem Mol Biol. 2017;173:105-116. doi:10.1016/j.jsbmb.2017.01.007

34. Chun RF, Peercy BE, Orwoll ES, et al. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 2014;144 Pt A:132-137. doi:10.1016/j.jsbmb.2013.09.012